<DOC>
	<DOC>NCT00171223</DOC>
	<brief_summary>This extension study will allow for further follow-up of the disease under treatment with imatinib mesylate and allow patients to continue to receive imatinib mesylate.</brief_summary>
	<brief_title>An Extension Study of the Safety and Anti-leukemic Effects of Imatinib Mesylate in Adult Patients With Ph + Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Myeloid</mesh_term>
	<mesh_term>Leukemia, Myeloid, Acute</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia, Lymphoid</mesh_term>
	<mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Successful completion of the CSTI571A 0110 E1 study Written informed consent for the extension CSTI571A0110E2 none Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Chronic Myelogenous Leukemia</keyword>
	<keyword>CML</keyword>
	<keyword>Philadelphia Chromosome</keyword>
	<keyword>Accelerated phase</keyword>
	<keyword>Acute Myelogenous Leukemia</keyword>
	<keyword>AML</keyword>
	<keyword>Acute Lymphoblastic Leukemia</keyword>
	<keyword>ALL</keyword>
	<keyword>Imatinib mesylate</keyword>
</DOC>